CareLit · DOI-Nachweis · Aktuelle Neurologie
O-(2-[18F]fluoroethyl)-L-tyrosine (FET) pet vs. stereotactic biopsy in glioma-patients after multimodal therapy: impact on treatment decision
DOI 10.1055/s-2005-919259
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ.H Mehrkens, G Poepperl, W Rachinger, K Tatsch, J.C Tonn, F.W Kreth
ZeitschriftAktuelle Neurologie
Ausgabe10/2005
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET has been reported to offer a promising diagnostic tool when differentiation between tumor- and therapy-associated contrast enhancement on MRI in patients with gliomas undergoing multimodal treatment is difficult. However, the impact of FET-PET findings on treatment decision remains uncertain and has yet to be evaluated. Methods: In a prospective study, a FET-PET…
Zitieren
Zitierempfehlung
J.H Mehrkens, G Poepperl, W Rachinger, K Tatsch, J.C Tonn, F.W Kreth (2005) O-(2-[18F]fluoroethyl)-L-tyrosine (FET) pet vs. stereotactic biopsy in glioma-patients after multimodal therapy: impact on treatment decision. Aktuelle Neurologie (10). https://doi.org/10.1055/s-2005-919259
Mit CareLit weiterarbeiten